SGIO.F Stock Overview
Engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Shionogi & Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥14.00 |
| 52 Week High | JP¥17.83 |
| 52 Week Low | JP¥12.21 |
| Beta | 0.28 |
| 1 Month Change | 14.01% |
| 3 Month Change | 4.28% |
| 1 Year Change | n/a |
| 3 Year Change | -34.39% |
| 5 Year Change | -26.92% |
| Change since IPO | 213.43% |
Recent News & Updates
Recent updates
Shareholder Returns
| SGIO.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -1.4% | -1.4% | 1.2% |
| 1Y | n/a | -1.8% | 23.7% |
Return vs Industry: Insufficient data to determine how SGIO.F performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how SGIO.F performed against the US Market.
Price Volatility
| SGIO.F volatility | |
|---|---|
| SGIO.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 18.0% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SGIO.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine SGIO.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1878 | 4,959 | Isao Teshirogi | www.shionogi.com |
Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug. It also develops S-872600 an influenza nasal vaccine; S-875670 anCOVID-19 nasal vaccine; S-540956 a nucleic acid adjuvant; S-554110 a nontuberculous mycobacterial infection; S-337395 for RSV infections; S-892216 for COVID-19 therapeutics; Olorofim for invasive aspergillosis; cefiderocol for aerobic gram-negative bacterial infections and infectious diseases; S-268019 a COVID-19 prophylactic vaccine; S-268019 a prophylactic vaccine for COVID-19; ensitrelvir for COVID-19 treatment and prevention; baloxavir for influenza virus infection; S-365598 for HIV infection; and S-555739 for suppressing aggravation of COVID-19.
Shionogi & Co., Ltd. Fundamentals Summary
| SGIO.F fundamental statistics | |
|---|---|
| Market cap | US$12.35b |
| Earnings (TTM) | US$1.11b |
| Revenue (TTM) | US$3.01b |
11.1x
P/E Ratio4.1x
P/S RatioIs SGIO.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SGIO.F income statement (TTM) | |
|---|---|
| Revenue | JP¥456.87b |
| Cost of Revenue | JP¥61.24b |
| Gross Profit | JP¥395.63b |
| Other Expenses | JP¥227.02b |
| Earnings | JP¥168.61b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 12, 2025
| Earnings per share (EPS) | 198.21 |
| Gross Margin | 86.60% |
| Net Profit Margin | 36.91% |
| Debt/Equity Ratio | 0% |
How did SGIO.F perform over the long term?
See historical performance and comparisonDividends
2.6%
Current Dividend Yield57%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/19 01:48 |
| End of Day Share Price | 2025/02/14 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Shionogi & Co., Ltd. is covered by 26 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Atsushi Seki | Barclays |
| Koichi Mamegano | BofA Global Research |
| Aaron Ho | CFRA Equity Research |